[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Anthrax (Infectious Disease) - Drugs in Development, 2021

March 2021 | 124 pages | ID: AE14A2B41A36EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Anthrax (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development, 2021, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Anthrax - Overview
Anthrax - Therapeutics Development
Anthrax - Therapeutics Assessment
Anthrax - Companies Involved in Therapeutics Development
Anthrax - Drug Profiles
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Anthrax, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Anthrax - Pipeline by Altimmune Inc, 2021
Anthrax - Pipeline by Aphios Corp, 2021
Anthrax - Pipeline by Aradigm Corp (Inactive), 2021
Anthrax - Pipeline by Biologics Resources LLC, 2021
Anthrax - Pipeline by BlueWillow Biologics Inc, 2021
Anthrax - Pipeline by China Biologic Products Holdings Inc, 2021
Anthrax - Pipeline by Crestone Inc, 2021
Anthrax - Pipeline by Dynavax Technologies Corp, 2021
Anthrax - Pipeline by Emergent BioSolutions Inc, 2021
Anthrax - Pipeline by GC Pharma, 2021
Anthrax - Pipeline by Greffex Inc, 2021
Anthrax - Pipeline by Hawaii Biotech Inc, 2021
Anthrax - Pipeline by iBio Inc, 2021
Anthrax - Pipeline by Innovative Biologics Inc, 2021
Anthrax - Pipeline by Integrated BioTherapeutics Inc, 2021
Anthrax - Pipeline by iNtRON Biotechnology Inc, 2021
Anthrax - Pipeline by Opal Biosciences Ltd, 2021
Anthrax - Pipeline by Paratek Pharmaceuticals Inc, 2021
Anthrax - Pipeline by Protein Potential LLC, 2021
Anthrax - Pipeline by ProThera Biologics Inc, 2021
Anthrax - Pipeline by Soligenix Inc, 2021
Anthrax - Pipeline by Vast Therapeutics Inc, 2021
Anthrax - Pipeline by Venomyx Inc, 2021
Anthrax - Pipeline by VLP Biotech Inc, 2021
Anthrax - Dormant Projects, 2021
Anthrax - Dormant Projects, 2021 (Contd..1)
Anthrax - Dormant Projects, 2021 (Contd..2)
Anthrax - Dormant Projects, 2021 (Contd..3)
Anthrax - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Anthrax, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021


More Publications